Drug Details
General Information of the Drug (ID: DR1849) | ||||
---|---|---|---|---|
Name |
Hydroxyurea
|
|||
Synonyms |
hydroxyurea; Hydroxycarbamide; 127-07-1; N-Hydroxyurea; Hydrea; 1-HYDROXYUREA; Oxyurea; Carbamoyl oxime; Biosupressin; Hydroxycarbamine; Urea, hydroxy-; Onco-carbide; Carbamohydroxamic acid; Carbamohydroximic acid; Carbamyl hydroxamate; Hydura; Litalir; Hydurea; N-Carbamoylhydroxylamine; Droxia; Hidrix; Hydroxicarbamidum; Siklos; Hydroxylurea; Hydreia; Litaler; Idrossicarbamide [DCIT]; Hidroxicarbamida; Hydroxyharnstoff; Hydroxycarbamidum; Carbamohydroxyamic acid; N-Hydroxymocovina; Hydroxylamine, N-carbamoyl-; SQ 1089; urea, N-hydroxy-; Hydroxyharnstoff [German]; N-Hydroxymocovina [Czech]; NCI-C04831; Hydroxylamine, N-(aminocarbonyl)-; SK 22591; Hydroxycarbamidum [INN-Latin]; Hidroxicarbamida [INN-Spanish]; HU; CCRIS 958; HYDROXY-UREA; NSC 32065; hydroxy urea; UNII-X6Q56QN5QC; NSC32065; MFCD00007943; AI3-51139; Hydroxyurea (Cytodrox); CHEMBL467; SQ-1089; X6Q56QN5QC; CHEBI:44423; Hydroxyurea, 98%; NSC-32065; Hydroxy Urea-15N; NCGC00015520-03; Hydroxycarbamid; Oncocarbide; Idrossicarbamide; DSSTox_CID_5438; DSSTox_RID_77787; DSSTox_GSID_25438; NHY; Hydroxyurea (D4); N-HYDROXY UREA; Mylocel; carbamide oxide; CAS-127-07-1; SMR000059149; Hydroxyurea (USP); Droxia (TM); Droxia (TN); Hydrea (TM); hydroxyaminomethanamide; HSDB 6887; SR-01000075919; DRG-0253; EINECS 204-821-7; HYDREA (TN); Hydroxyurea [USAN:USP]; BRN 1741548; Hydroxycarbamide (JAN/INN); hydroxyl urea; Xromi; 1-oxidanylurea; S-phase/G-1 interface inhibitor; 15N Hydroxyurea; aminohydroxamic acid; carbamic acid oxime; Carbomohydroxamic acid; Spectrum_000909; Hydroxycarbamide [INN]; WLN: ZVMQ; Hydrea (Bristol Meyers); Spectrum2_000064; Spectrum3_000462; Spectrum4_000012; Spectrum5_000836; Lopac-H-8627; MolMap_000029; H 8627; NCIMech_000139; Hydroxyurea, 98%, powder; ACMC-1C22W; Lopac0_000596; BSPBio_002164; KBioGR_000383; KBioSS_001389; 4-03-00-00170 (Beilstein Handbook Reference); 8029-68-3; hydroxycarbamide (hydroxyurea); MLS001332381; MLS001332382; MLS002153389; DivK1c_000556; N-(Aminocarbonyl)hydroxylamine; SPECTRUM1500344; SPBio_000247; GTPL6822; NC(=O)N[O]; DTXSID6025438; tetratogen: inhibits ribonucleoside diphosphate reductase; HMS501L18; KBio1_000556; KBio2_001389; KBio2_003957; KBio2_006525; KBio3_001384; NINDS_000556; Bio1_000451; Bio1_000940; Bio1_001429; HMS1920F09; HMS2091L17; HMS2234I03; HMS3261H14; HMS3373G18; HMS3655K20; HMS3869C03; NCI C04831; Pharmakon1600-01500344; ACT02611; ALBB-028465; AMY40858; EBD12517; HY-B0313; STR02555; ZINC8034120; Tox21_110168; Tox21_300319; Tox21_500596; ANW-18958; BBL009928; BDBM50017811; CCG-35236; NSC757072; s1896; STL145898; AKOS005716276; AKOS006222547; Tox21_110168_1; ZINC100019199; DB01005; LP00596; MCULE-9465284053; NSC-757072; SDCCGSBI-0050578.P006; IDI1_000556; NCGC00015520-01; NCGC00015520-02; NCGC00015520-04; NCGC00015520-05; NCGC00015520-06; NCGC00015520-07; NCGC00015520-08; NCGC00015520-09; NCGC00015520-10; NCGC00015520-11; NCGC00015520-20; NCGC00093974-01; NCGC00093974-02; NCGC00093974-03; NCGC00093974-04; NCGC00093974-05; NCGC00254007-01; NCGC00261281-01; AC-22674; AK128930; NCI60_002773; SBI-0050578.P004; AB0013265; DB-041849; EU-0100596; FT-0627160; FT-0627175; FT-0670210; SW218071-2; C07044; D00341; Hydroxyurea, Vetec(TM) reagent grade, >=98%; AB00052018-09; AB00052018-10; AB00052018_11; AB00052018_12; 127H071; A805636; Q212272; J-504798; SR-01000075919-1; SR-01000075919-3; SR-01000075919-8; E0723DBA-5AF3-49D1-B5F6-59420AB87AC9; F8880-0905; Z1522566612; Hydroxycarbamide, European Pharmacopoeia (EP) Reference Standard; Hydroxyurea, United States Pharmacopeia (USP) Reference Standard
Click to Show/Hide
|
|||
Molecular Type |
Small molecule
|
|||
Disease | Chronic myelogenous leukaemia [ICD-11: 2A20] | Approved | [1] | |
Structure |
Click to Download Mol2D MOL |
|||
Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | ||||
Formula |
CH4N2O2
|
|||
PubChem CID | ||||
Canonical SMILES |
C(=O)(N)NO
|
|||
InChI |
1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
|
|||
InChIKey |
VSNHCAURESNICA-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 127-07-1
|
|||
ChEBI ID | ||||
TTD Drug ID | ||||
DrugBank ID |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. A List of Natural Product(s) Able to Enhance the Efficacy of This Drug | ||||||
Acitretin | Homo sapiens | Click to Show/Hide the Molecular Data of This NP | ||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Representative Experiment Reporting the Effect of This Combination | [2] | |||||
Detail(s) | Combination Info click to show the detail info of this combination | |||||
Experimental
Result(s) |
Hydroxyurea and acitretin as a novel combination therapy in severe plaque psoriasis. |
Target and Pathway | ||||
---|---|---|---|---|
Target(s) | Ribonucleoside-diphosphate reductase M2 (RRM2) | Molecule Info | [3] | |
BioCyc | Pyrimidine deoxyribonucleotides biosynthesis from CTP | Click to Show/Hide | ||
2 | Pyrimidine deoxyribonucleotides de novo biosynthesis | |||
3 | Guanosine nucleotides de novo biosynthesis | |||
4 | Superpathway of pyrimidine deoxyribonucleotides de novo biosynthesis | |||
5 | Superpathway of purine nucleotide salvage | |||
6 | Purine nucleotides de novo biosynthesis | |||
7 | Adenosine deoxyribonucleotides de novo biosynthesis | |||
8 | Guanosine deoxyribonucleotides de novo biosynthesis | |||
KEGG Pathway | Purine metabolism | Click to Show/Hide | ||
2 | Pyrimidine metabolism | |||
3 | Glutathione metabolism | |||
4 | Metabolic pathways | |||
5 | p53 signaling pathway | |||
NetPath Pathway | EGFR1 Signaling Pathway | Click to Show/Hide | ||
Panther Pathway | p53 pathway | Click to Show/Hide | ||
2 | De novo purine biosynthesis | |||
3 | De novo pyrimidine deoxyribonucleotide biosynthesis | |||
Pathwhiz Pathway | Purine Metabolism | Click to Show/Hide | ||
2 | Pyrimidine Metabolism | |||
Pathway Interaction Database | E2F transcription factor network | Click to Show/Hide | ||
Reactome | E2F mediated regulation of DNA replication | Click to Show/Hide | ||
2 | G1/S-Specific Transcription | |||
WikiPathways | Nucleotide Metabolism | Click to Show/Hide | ||
2 | Retinoblastoma (RB) in Cancer | |||
3 | Metabolism of nucleotides | |||
4 | Fluoropyrimidine Activity |